{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:56:03Z","timestamp":1770155763610,"version":"3.49.0"},"reference-count":71,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T00:00:00Z","timestamp":1481155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bronchiectasis, a chronic lung disease characterised by cough and purulent sputum, recurrent infections, and airway damage, is associated with considerable morbidity and mortality. To date, treatment options have been limited to physiotherapy to clear sputum and antibiotics to treat acute infections. Over the last decade, there has been significant progress in understanding the epidemiology, pathophysiology, and microbiology of this disorder. Over the last five years, methods of assessing severity have been developed, the role of macrolide antibiotic therapy in reducing exacerbations cemented, and inhaled antibiotic therapies show promise in the treatment of chronic Pseudomonas aeruginosa infection. Novel therapies are currently undergoing Phase 1 and 2 trials. This review aims to address the major developments within the field of bronchiectasis over this time.<\/jats:p>","DOI":"10.3390\/jcm5120115","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T10:39:01Z","timestamp":1481193541000},"page":"115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Bronchiectasis in the Last Five Years: New Developments"],"prefix":"10.3390","volume":"5","author":[{"given":"Jun","family":"Khoo","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Western Health, Melbourne 3011, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Venning","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Prince of Wales, Sydney 2031, NSW, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conroy","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Middlemore Hospital, Auckland 2025, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lata","family":"Jayaram","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Western Health, Melbourne 3011, VIC, Australia"},{"name":"Melbourne Medical School Western Precinct, The University of Melbourne, Melbourne 3021, VIC, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5694\/mja14.00287","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines","volume":"202","author":"Chang","year":"2015","journal-title":"Med. J. Aust."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British thoracic society guideline for non-cf bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"ref_3","first-page":"P3983","article-title":"Global burden of non-cystic fibrosis bronchiectasis: A simple epidemiological analysis","volume":"40","author":"Polverino","year":"2012","journal-title":"ERJ"},{"key":"ref_4","first-page":"376","article-title":"Respiratory disease in canadian first nations and inuit children","volume":"17","author":"Kovesi","year":"2012","journal-title":"Paediatr. Child Health"},{"key":"ref_5","first-page":"30","article-title":"Hospital admissions for non-cystic fibrosis bronchiectasis in new zealand","volume":"128","author":"Bibby","year":"2015","journal-title":"N. Z. Med. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/j.1445-5994.2011.02444.x","article-title":"Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis","volume":"42","author":"Roberts","year":"2012","journal-title":"Intern. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2007.03.009","article-title":"Microbiologic follow-up study in adult bronchiectasis","volume":"101","author":"King","year":"2007","journal-title":"Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1081\/COPD-200050685","article-title":"Outcome in adult bronchiectasis","volume":"2","author":"King","year":"2005","journal-title":"COPD"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.rmed.2013.04.013","article-title":"Phenotyping adults with non-cystic fibrosis bronchiectasis: A prospective observational cohort study","volume":"107","author":"Anwar","year":"2013","journal-title":"Respir. Med."},{"key":"ref_10","first-page":"1602","article-title":"A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1513\/AnnalsATS.201507-472OC","article-title":"Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity","volume":"12","author":"Lonni","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/resp.12832","article-title":"Aetiology of bronchiectasis in adults: A systematic literature review","volume":"21","author":"Gao","year":"2016","journal-title":"Respirology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201208-1518OC","article-title":"Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease","volume":"187","author":"Serra","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4187\/respcare.01857","article-title":"Coexistence of bronchiectasis and rheumatoid arthritis: Revisited","volume":"58","author":"Wilczynska","year":"2013","journal-title":"Respir. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1183\/13993003.01862-2015","article-title":"Asthma and bronchiectasis exacerbation","volume":"47","author":"Mao","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1513\/AnnalsATS.201310-335OC","article-title":"A novel microbiota stratification system predicts future exacerbations in bronchiectasis","volume":"11","author":"Rogers","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.rmed.2014.07.021","article-title":"Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of pseudomonas persistence and resistance","volume":"109","author":"McDonnell","year":"2015","journal-title":"Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1164\/rccm.201210-1937OC","article-title":"Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation","volume":"187","author":"Tunney","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(14)61136-3","article-title":"The role of the microbiome in exacerbations of chronic lung diseases","volume":"384","author":"Dickson","year":"2014","journal-title":"Lancet"},{"key":"ref_20","first-page":"A2879","article-title":"Altered lung microbiota profiles are associated with disease severity, exacerbation frequency and neutrophilic inflammation in bronchiectasis","volume":"193","author":"Dicker","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cox, M.J., Turek, E.M., Hennessy, C., Mirza, G.K., James, P.L., Coleman, M., Jones, A., Wilson, R., Bilton, D., and Cookson, W.O.C.M. (2016). Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cf bronchiectasis patients. bioRxiv.","DOI":"10.1101\/050237"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: An analysis from the randomised, double-blind, placebo-controlled bless trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1183\/13993003.01899-2015","article-title":"Clinical phenotypes in adult patients with bronchiectasis","volume":"47","author":"Aliberti","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1513\/AnnalsATS.201510-678OC","article-title":"The multiple faces of non-cystic fibrosis bronchiectasis: A cluster analysis approach","volume":"13","author":"Vendrell","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1513\/AnnalsATS.201512-797OC","article-title":"Airway Mucin 2 is decreased in patients with severe COPD patients with bacterial colonization","volume":"13","author":"Sibila","year":"2016","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/resp.12595","article-title":"Secreted mucins and airway bacterial colonization in non-cf bronchiectasis","volume":"20","author":"Sibila","year":"2015","journal-title":"Respirology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1465-9921-11-122","article-title":"Characterisation of COPD heterogeneity in the ECLIPSE cohort","volume":"11","author":"Agusti","year":"2010","journal-title":"Respir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1378\/chest.10-1758","article-title":"Factors associated with bronchiectasis in patients with copd","volume":"140","year":"2011","journal-title":"Chest"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2466-14-103","article-title":"Pseudomonas aeruginosaisolates in severe chronic obstructive pulmonary disease: Characterization and risk factors","volume":"14","author":"Gallego","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1164\/rccm.200305-648OC","article-title":"Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Patel","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_31","first-page":"795","article-title":"Characteristics and self-rated health of overlap syndrome","volume":"9","author":"Chung","year":"2014","journal-title":"Int. J. COPD"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","article-title":"Quality of life questionnaire-bronchiectasis: Final psychometric analyses and determination of minimal important difference scores","volume":"70","author":"Quittner","year":"2015","journal-title":"Thorax"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to non-cystic fibrosis bronchiectasis: The faced score","volume":"43","author":"Giron","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"McDonnell, M.J., Aliberti, S., Goeminne, P.C., Dimakou, K., Zucchetti, S.C., Davidson, J., Ward, C., Laffey, J.G., Finch, S., and Pesci, A. (2016). Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts. Thorax.","DOI":"10.1183\/13993003.congress-2016.OA274"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1183\/13993003.01312-2015","article-title":"Predicting mortality in bronchiectasis using bronchiectasis severity index and faced scores: A 19-year cohort study","volume":"47","author":"Ellis","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lee, A.L., Burge, A.T., and Holland, A.E. (2013). Airway clearance techniques for bronchiectasis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD008351.pub2"},{"key":"ref_38","unstructured":"Lee, A.L., Hill, C.J., McDonald, C.F., and Holland, A.E. (2016). Pulmonary Rehabilitation in Individuals with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review. Arch. Phys. Med. Rehabil."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000320320","article-title":"Immunomodulatory effects of macrolide antibiotics\u2014Part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy","volume":"81","author":"Altenburg","year":"2011","journal-title":"Respiration"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (embrace): A randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The bat randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The bless randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-2600(13)70185-1","article-title":"Long-term azithromycin for indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (bronchiectasis intervention study): A multicentre, double-blind, randomised controlled trial","volume":"1","author":"Valery","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gao, Y.H., Guan, W.J., Xu, G., Tang, Y., Gao, Y., Lin, Z.Y., Lin, Z.M., Zhong, N.S., and Chen, R.C. (2014). Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090047"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/resp.12233","article-title":"Long-term macrolides for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis","volume":"19","author":"Wu","year":"2014","journal-title":"Respirology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"708608","DOI":"10.1155\/2014\/708608","article-title":"Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis","volume":"2014","author":"Liu","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstrom","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other antibacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","article-title":"Macrolide antibiotics and the risk of cardiac arrhythmias","volume":"189","author":"Albert","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijantimicag.2012.05.018","article-title":"Impact of recent antibiotics on nasopharyngeal carriage and lower airway infection in Indigenous Australian children with non-cystic fibrosis bronchiectasis","volume":"40","author":"Hare","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hill, A.T. (2016). Macrolides for Clinically Significant Bronchiectasis in Adults: Who Should Receive this Treatment?. Chest.","DOI":"10.1016\/j.chest.2016.08.1451"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: A systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_57","first-page":"1420","article-title":"A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis","volume":"127","author":"Scheinberg","year":"2005","journal-title":"Chest"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hoppentocht, M., Akkerman, O.W., Hagedoorn, P., Alffenaar, J.W., van der Werf, T.S., Kerstjens, H.A., Frijlink, H.W., and de Boer, A.H. (2016). Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149768"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase ii randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (orbit-2): A randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_64","first-page":"CD002996","article-title":"Inhaled hyperosmolar agents for bronchiectasis","volume":"5","author":"Hart","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: A randomised, controlled trial","volume":"69","author":"Bilton","year":"2014","journal-title":"Thorax"},{"key":"ref_66","first-page":"CD001289","article-title":"Mucolytics for bronchiectasis","volume":"5","author":"Wilkinson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmed.2012.12.009","article-title":"Phase ii study of a neutrophil elastase inhibitor (azd9668) in patients with bronchiectasis","volume":"107","author":"Stockley","year":"2013","journal-title":"Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/thx.2005.057976","article-title":"Potential therapeutic role for statins in respiratory disease","volume":"61","author":"Hothersall","year":"2006","journal-title":"Thorax"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: A randomized controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1183\/13993003.00148-2015","article-title":"A randomised, placebo-controlled study of the cxcr2 antagonist azd5069 in bronchiectasis","volume":"46","author":"Pavord","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1183\/13993003.01888-2015","article-title":"Research priorities in bronchiectasis: A consensus statement from the embarc clinical research collaboration","volume":"48","author":"Aliberti","year":"2016","journal-title":"Eur. Respir. J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/5\/12\/115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:28:12Z","timestamp":1760210892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/5\/12\/115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":71,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["jcm5120115"],"URL":"https:\/\/doi.org\/10.3390\/jcm5120115","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]}}}